| Literature DB >> 34173097 |
V Kh Khavinson1, N S Lin'kova2,3,4, R S Umnov1.
Abstract
Neuroprotective peptides are promising candidate molecules for the treatment of Alzheimer's disease (AD). Oral application of KED (Lys-Glu-Asp) improved memory and attention in elderly individuals with functional CNS disorders. Peptide KED also restores synaptic plasticity in in vitro model of AD. This review is focused on the analysis of the influence of KED peptide on the expression of genes and synthesis of proteins regulating apoptosis, aging, neurogenesis, and involved in AD pathogenesis. Analysis of published reports and our experimental findings suggests that KED regulates the expression of genes of cell aging and apoptosis (р16, р21), genes (NES, GAP43) and proteins (nestin, GAP43) of the neuronal differentiation, and genes involved in AD pathogenesis (SUMO, APOE, and IGF1). The study the effectiveness of neuroprotective peptide KED in animal models of AD seems to be very important.Entities:
Keywords: Alzheimer’s disease; gene expression; neuroprotection; peptide KED
Mesh：
Substances：
Year: 2021 PMID： 34173097 DOI： 10.1007/s10517-021-05192-6
Source DB: PubMed Journal: Bull Exp Biol Med ISSN： 0007-4888 Impact factor: 0.804